AI
VRDN icon

Atom Investors’s Viridian Therapeutics VRDN Stock Holding History

Atom Investors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,470
Closed -$419K – 856
2025
Q4 		$419K Buy
+13,470
New +$369K 0.03% 402
2022
Q3 		– Sell
-10,699
Closed -$124K – 374
2022
Q2 		$124K Sell
10,699
-5,407
-34% -$72.7K 0.05% 211
2022
Q1 		$298K Sell
16,106
-2,778
-15% -$53.4K 0.14% 140
2021
Q4 		$373K Buy
+18,884
New +$352K 0.06% 186

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Atom Investors's VRDN Position: Q1 2026 in Review

Atom Investors sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 13,470 shares — an estimated $419K sold.

Atom Investors first reported a position in VRDN in Q4 2021 and held it in 4 quarters. The position peaked at $419K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Atom Investors reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Atom Investors sold 13,470 Viridian Therapeutics shares in Q1 2026, an estimated $419K.
  • Atom Investors first reported a position in Viridian Therapeutics in Q4 2021 and held it in 4 quarters.
  • Atom Investors's Viridian Therapeutics position peaked at $419K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.